Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema
| Autor: | Regina Treudler, Marcus Puder, Jan-Christoph Simon, Michael Szardenings, Nicolas Delaroque |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Phage display
0211 other engineering and technologies Eczema 02 engineering and technology Dermatology Antibodies Monoclonal Humanized Epitope Dermatitis Atopic 03 medical and health sciences Serum Sickness 0302 clinical medicine Medicine Humans In patient Adverse effect 021110 strategic defence & security studies biology business.industry SERUM SICKNESS-LIKE REACTION Interleukin Dupilumab Infectious Diseases 030228 respiratory system Immunology biology.protein Antibody business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology : JEADV. 35(1) |
| ISSN: | 1468-3083 |
| Popis: | Dupilumab is a fully humanized Immunoglobulin-(Ig)-G4 antibody against the interleukin (IL)-4α subunit of the IL-4- and the IL-13-receptor.1 In patients with atopic eczema (AE), most frequent adverse reactions include injection site reactions and conjunctivitis/blepharitis.1,2 Recently, a case with suspicion of an IgE-mediated hypersensitivity was reported.3 We herein report upon a patient who developed serum sickness like reaction (SSLR) under therapy with dupilumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text